Rubedo Pharmaceuticals is developing an emergency nanoparticle-based blood substitute known as QuikBlood that will be engineered both in freeze‐dried and whole fluid formulations.
Karma Biotechnologies is developing nanotechnologies that can engineer and repair tissues and tumors at the cellular level.
Xcell Unity is developing the next generation of immunotherapy for refractory cancer with minimal toxicity & enduring remission for the majority of treated patients.
Interested in our current portfolio startups? Contact us today!
Interested in applying to BioBuilt to accelerate your startup biotech? Apply here